The Integration Abyss By Dr Scott D. Kahn The long-standing disconnect between target discovery/characterisation and compound discovery is a major challenge facing the pharmaceutical industry in its quest to develop innovative therapies from the wealth of information flowing from the human genome. There is enormous interest within the pharmaceutical and biotechnology industry to better utilise […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!